Evidence-based medicine

ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update

Retrieved on: 
Wednesday, May 6, 2020
Evidence-based medicine, Precision medicine, Systems biology, Cash and cash equivalents, Cardiovascular disease

Subject to securing additional financing, ARCA anticipates initiating PRECISION-AF in the fourth quarter of 2020.

Key Points: 
  • Subject to securing additional financing, ARCA anticipates initiating PRECISION-AF in the fourth quarter of 2020.
  • Cash and cash equivalents were $6.7 million as of March 31, 2020, compared to $8.4 million as of December 31, 2019.
  • ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.
  • ARCA disclaims any intent or obligation to update these forward-looking statements.

Guardant Health to Participate in the BofA Securities 2020 Healthcare Conference

Retrieved on: 
Wednesday, May 6, 2020
Evidence-based medicine, Precision medicine, Systems biology, Oncology

REDWOOD CITY, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference.

Key Points: 
  • REDWOOD CITY, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference.
  • Guardant Healths management is scheduled for a fireside on Wednesday, May 13th at 1:20 p.m. Pacific Time / 4:20 p.m. Eastern Time.
  • Guardant Healthis a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics.
  • The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.Guardant Healthhas launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients.

Black Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020

Retrieved on: 
Wednesday, May 6, 2020
Evidence-based medicine, Precision medicine, Systems biology

and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys business at the Bank of America Global Research Health Care Conference 2020.

Key Points: 
  • and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys business at the Bank of America Global Research Health Care Conference 2020.
  • The presentation will take place on Tuesday, May 12, 2020, at 4:20 PM ET.
  • Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

Kura Oncology Reports First Quarter 2020 Financial Results

Retrieved on: 
Monday, May 4, 2020
Evidence-based medicine, Precision medicine, Systems biology, Oncology, Life sciences

ET

Key Points: 
  • ET
    SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2020 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2020 were $12.6 million, compared to $10.4 million for the first quarter of 2019.
  • ET / 1:30 p.m. PT today, May 4, 2020, to discuss the financial results for the first quarter 2020 and provide a corporate update.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

BostonGene and Washington University in St. Louis Collaborate on Kidney Cancer Research

Retrieved on: 
Thursday, April 30, 2020
Oncology, Health, Technology, Software, Research, Science, Biotechnology, Branches of biology, Health, Systems biology, Medicine, Evidence-based medicine, Precision medicine, Tumor microenvironment, Renal cell carcinoma

BostonGene Corporation, a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced it has expanded its research collaboration with Washington University in St. Louis to study renal cell carcinoma (RCC).

Key Points: 
  • BostonGene Corporation, a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced it has expanded its research collaboration with Washington University in St. Louis to study renal cell carcinoma (RCC).
  • BostonGenes software uses a set of unique deconvolution algorithms that reveal cellular content of a tumor and surrounding microenvironment using transcriptome next generation sequencing (NGS) data.
  • Addition of the image analysis component elucidates cellular architecture and spatial localization of tumor, immune and stromal cells.
  • BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

DiscernDx Acquires Luminist Labs to Expand Precision Medicine Solutions for Chronic Diseases

Retrieved on: 
Wednesday, April 29, 2020
Software, Research, Other Health, Internet, Pharmaceutical, Data management, Technology, Clinical trials, Science, Biotechnology, Other Technology, Health, Other Science, Branches of biology, Medical terminology, Biology, Evidence-based medicine, Precision medicine, Systems biology, Multiomics, Medicine, Disease, Chronic condition, Omics, Metabolic disorder

DiscernDx, today announced the expansion of the companys precision medicine solutions with the acquisition of Luminist Labs, a privately-held novel diagnostic platform company for the early detection and diagnosis of liver disease.

Key Points: 
  • DiscernDx, today announced the expansion of the companys precision medicine solutions with the acquisition of Luminist Labs, a privately-held novel diagnostic platform company for the early detection and diagnosis of liver disease.
  • The acquisition will be integrated into the DiscernDx multi-omics platform to develop a deeper understanding of chronic metabolic diseases and create new precision medicine paradigms for physicians and patients.
  • This acquisition builds on DiscernDx precision medicine solutions and is a natural extension of our patient offering.
  • Our team will continue expanding our system, to create precision medicine solutions for the 1 in 2 Americans living with chronic metabolic diseases.

Ascend Learning Clinical Healthcare offers complimentary access to suite of innovative virtual training and simulated case study exercises

Retrieved on: 
Monday, April 27, 2020
Articles, Healthcare quality, Health, Health informatics, Modeling and simulation, Simulation, Medical guideline, Evidence-based medicine, Artificial intelligence

To facilitate healthcare professional and student success, Ascend Learning Clinical Healthcare is launching a suite of complimentary, evidence-based clinical training simulations developed by Ascend Learning sister organizations.

Key Points: 
  • To facilitate healthcare professional and student success, Ascend Learning Clinical Healthcare is launching a suite of complimentary, evidence-based clinical training simulations developed by Ascend Learning sister organizations.
  • This series of effective, scalable and data-driven solutions will be available free of charge through May 15.
  • Insight to Action solutionsuse assessments and simulated case studies to develop and hone professional skills, specifically around adherence to accepted care guidelines.
  • Insight to Action, powered by QURE, complimentary case studies include:
    Kognito solutionsuse evidence-based patient simulations, enabling participants to virtually engage in role-playing conversations with AI-powered virtual humans.

Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform

Retrieved on: 
Monday, April 27, 2020
Branches of biology, Biology, Biomarkers, Evidence-based medicine, Precision medicine, Systems biology, Bioinformatics, Brachyury

The grant will be executed in a consortium with Ardigen bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine.

Key Points: 
  • The grant will be executed in a consortium with Ardigen bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine.
  • This grant provides Selvita and Ardigen with almost EUR 1.05 million of non-dilutive financing.
  • Selvita will be responsible for the development of two sets of cellular tests from specified therapeutic areas capable of generating images for artificial intelligence system analysis.
  • The company's in-house datasets together with platforms for immunology, biomarker, and microbiome research can empower effective pharmaceuticals development.

Indivumed, Personalis Partner to Enhance Genomic Sequencing Capabilities

Retrieved on: 
Tuesday, April 21, 2020
Biotechnology, Medical devices, Health, Pharmaceutical, Oncology, Branches of biology, Biology, Life sciences, Systems biology, Evidence-based medicine, Precision medicine, Genomics, DNA sequencing, Indivumed, Personalis, Inc.

Adding Personalis technology to the IndivuType multiomics profile will enable relevant discoveries in our collaborations with pharma and biotech and further our mission to advance precision oncology.

Key Points: 
  • Adding Personalis technology to the IndivuType multiomics profile will enable relevant discoveries in our collaborations with pharma and biotech and further our mission to advance precision oncology.
  • Pairing these high-quality samples with Personalis innovative and robust solutions for comprehensive tumor genomics characterization has the potential to provide deeper insights into oncology therapeutics.
  • Working with Indivumed on this program will allow us to deliver broad, more comprehensive genomic sequencing for cancer that can ultimately fuel drug discovery and development, said John West, CEO of Personalis.
  • Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes.

IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team

Retrieved on: 
Tuesday, April 21, 2020
Evidence-based medicine, Precision medicine, Systems biology

Ms. Patel will join the IDEAYA leadership team and will have broad functional responsibilities for human resources within the company.

Key Points: 
  • Ms. Patel will join the IDEAYA leadership team and will have broad functional responsibilities for human resources within the company.
  • "We are thrilled to have Julie join our leadership team at IDEAYA.
  • Julie has extensive experience as a human resources professional at world-class biopharmaceutical companies.
  • "I am ecstatic to join the IDEAYA team, and to support its efforts to build a leading precision medicine oncology company.